… American Academy of Optometry (AAOpt) Annual Meeting 2020 American Academy of … 2020 ProQR to participate in the American Academy of Optometry (AAOpt) Annual Meeting 2020 . wo 07-10-2020 - 00:00 …
Applicability of a structure-based modelling approach as a tool for in silico screening of oligonucleotides for targeted RNA editing presented at Oligonucleotide Therapeutics Society (OTS) 2018 by Julien Boudet
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands … are available on the SEC’s website, located at www.sec.gov . Copies of the final prospectus supplement and the …
… which we process data We collect information in order to optimize our services offered to you and we do it in a manner … so we can address your inquiries with us, we have provided options and contact details that enable you to contact us. … receive our letters. Each mailing contains the option to opt-out. As soon as you opt-out, your name and e-mail address …
… had an incurable rare disease, he founded ProQR to help people like his son. Learn more. A personal mission A … Daniel sought help from experts in the field of drug development and formed ProQR to help people like his son. … people living with rare diseases who have no treatment options. Henri Termeer To learn more about Henri, visit the …
ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
